Clinical evaluation of Ketotifen (Zaditen) in perennial and seasonal allergic rhinitis.

概要

論文の詳細を見る
The effectiveness and safety of Ketotifen in the treatment of perennial and seasonal allergic rhinitis were evaluated. Ketotifen 1mg was orally given twice a day to 26 patients with perennial allergic rhinitis (Group A) and 17 patients with seasonal allergic rhinitis (Group B) for 4 consecutive weeks in principal.In the global evaluation, the effective rate was 92.3% in Group A and 52.9% in Group B. The utility rate was 88.4% in Group A and 52.9% in Group B. Therapeutic effects appeared within 3 weeks in 84.6% of those in Group A and in 52.9% of those in Group B.Three major symptoms of allergic rhinitis were objectively evaluated. In Group A, 70.8% had fewer sneezing attacks, 76.0% less nasal discharge, 68.0% fewer attacks of nasal obstruction. In Group B, 47.0% had fewer sneezing attacks, 50.0% less nasal discharge, 46.6% fewer attacks of nasal obstruction.In regard to side effects, drowsiness was noted in 3 patients (7.0%). Ketotifen was more useful for perennial allergic rhinitis than the seasonal type.